Failure to complete tamoxifen course

Half of all women taking tamoxifen fail to complete the five-year treatment course, according to a retrospective cohort study of all women with incident breast cancer in Tayside, Scotland, carried out between 1993 and 2002. The median duration of use among the 1,633 women in the study who were prescribed the drug was 2.42 years. Adherence below 80 per cent was associated with poorer survival (HR 1.10, 95% CI 1.001-1.21). Only 49 per cent of women taking the drug continued therapy for five years and younger women were more likely to stop early.

McCowan C, Shearer J, Donnan PT et al. Br J Cancer 2008;doi:10.1038/sj.bjc.6604758

Originally published in the November 2008 edition of MIMS Oncology & Palliative Care.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs